文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急诊科急性疼痛中镇痛与亚解离剂量氯胺酮的疗效

Efficacy of analgesic and sub-dissociative dose ketamine for acute pain in the emergency department.
PubMed 文献 · Am J Emerg Med · 2023-05-26
一句话结论急诊急性疼痛中,亚解离剂量氯胺酮低剂量(<0.3 mg/kg)与高剂量(≥0.3 mg/kg)的镇痛效果与安全性无差异,低剂量是有效且安全的疼痛管理策略。

这项多中心回顾性队列研究在四个州21个急诊科纳入384例接受亚解离剂量氯胺酮(0.1-0.6 mg/kg)治疗的成年急性疼痛患者,按剂量分为低剂量组(<0.3 mg/kg,258例)和高剂量组(≥0.3 mg/kg,126例)。主要终点为60分钟内11点数字评分量表(NRS)疼痛评分变化,两组分别下降2.2和2.6分,组间差异0.4(95%CI -0.4至1.1,p=0.34),无统计学显著差异。补救镇痛药使用率(40.7% vs 36.5%,p=0.43)和不良反应(如烦躁7.3%、恶心7.0%)组间相似。结论认为高剂量亚解离氯胺酮并不优于低剂量,低剂量<0.3 mg/kg是有效且安全的疼痛管理策略。

要点

  • 急诊成年急性疼痛患者中,低剂量(<0.3 mg/kg)与高剂量(≥0.3 mg/kg)亚解离氯胺酮60分钟内NRS疼痛评分下降无显著差异(-2.2 vs -2.6,平均差0.4,95%CI -0.4至1.1,p=0.34)。
  • 两组补救镇痛药使用率相似(低剂量组40.7% vs 高剂量组36.5%,p=0.43),提前终止氯胺酮输注比例也相似(37.2% vs 37.3%,p=0.99)。
  • 总体最常见不良反应为烦躁(7.3%)和恶心(7.0%),组间不良反应无差异。
  • 基线疼痛评分低剂量组中位数8.2 vs 高剂量组7.8(差值0.5,95%CI 0至1,p=0.04)。
  • 低剂量氯胺酮<0.3 mg/kg是急诊急性疼痛有效且安全的疼痛管理策略。

适用人群与场景

  • 2018年5月5日至2021年8月30日在四个州的21个急诊科(学术、社区和危重通道医院)接受镇痛和亚解离剂量氯胺酮治疗急性疼痛的成年患者。
  • 排除因疼痛以外的适应证(如操作镇静或插管)接受氯胺酮的患者,或主要结局记录不完整的患者。

诊断标准与关键阈值

  • 采用标准11点数字评分量表(NRS)评估疼痛。
  • 氯胺酮剂量<0.3 mg/kg为低剂量组,≥0.3 mg/kg为高剂量组。

处置流程与药物剂量

  • 静脉注射亚解离剂量氯胺酮(0.1-0.6 mg/kg)用于急诊急性疼痛管理。

研究设计与关键结果

  • 研究类型为多中心回顾性队列研究,筛查3796例接受氯胺酮的患者,最终纳入384例,其中低剂量组258例、高剂量组126例。
  • 主要终点:60分钟内NRS疼痛评分变化,低剂量组-2.2 vs 高剂量组-2.6,平均差0.4(95%CI -0.4至1.1,p=0.34),无显著差异。
  • 基线疼痛评分中位数:低剂量组8.2 vs 高剂量组7.8(差值0.5,95%CI 0至1,p=0.04)。
  • 补救镇痛药使用率:低剂量组40.7% vs 高剂量组36.5%(p=0.43)。
  • 提前终止氯胺酮输注:低剂量组37.2% vs 高剂量组37.3%(p=0.99)。
  • 最常见不良反应:烦躁7.3%、恶心7.0%,组间不良反应相似。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急诊成年急性疼痛患者,高剂量亚解离氯胺酮(≥0.3 mg/kg)的镇痛疗效和安全性不优于低剂量(<0.3 mg/kg);低剂量氯胺酮<0.3 mg/kg是有效且安全的疼痛管理策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute pain accounts for over 70% of Emergency Department (ED) visits. Sub-dissociative dose ketamine (0.1-0.6 mg/kg) is safe and effective for the management of acute pain in the ED. However, the optimal dose of intravenous ketamine that provides effective analgesia and minimizes the risk of adverse effects has yet to be identified. The objective of this study was to describe an effective analgesia dose range of IV ketamine for acute pain in the ED.

METHODS: This multi-center, retrospective cohort study evaluated adult patients who received analgesic and sub-dissociative dose ketamine for the management of acute pain between May 5, 2018, and August 30, 2021, in 21 emergency departments at academic, community, and critical access hospitals across four states. Patients were excluded if they received ketamine for an indication other than pain, such as procedural sedation or intubation, or for whom there was incomplete documentation for the primary outcome. Patients who received a ketamine dose <0.3 mg/kg were stratified into the low-dose group, and those who received a dose of 0.3 mg/kg or higher to the high-dose group. The primary outcome was change in pain scores within 60 min using a standard 11-point numeric rating scale (NRS). Secondary outcomes included incidence of adverse effects and use of rescue analgesics. Continuous variables were compared between dose groups using student t-test or Wilcoxon Rank-Sum test. Linear regression was used to assess the association between the change in NRS pain scores within 60 min and dose after adjusting for baseline pain, requiring an additional dose of ketamine, and receiving an opioid.

RESULTS: From 3796 patient encounters screened for receipt of ketamine, 384 patients met inclusion criteria including 258 in the low-dose group, and 126 in the high-dose group. The primary reason for exclusion was incomplete documentation of pain scores, or ketamine used for sedation. Median baseline pain scores were 8.2 in the low-dose group and 7.8 in the high-dose group (difference 0.5; 95% CI 0 to 1, p = 0.04). Both groups demonstrated significant reductions in their mean NRS pain scores within 60 min following the first administration of IV ketamine. There were no differences in the change in pain scores between both groups (-2.2 vs -2.6, mean difference 0.4, 95% CI -0.4 to 1.1, p = 0.34). Use of rescue analgesics (40.7% vs 36.5%, p = 0.43) and adverse effects were similar between groups, including early discontinuation of the ketamine infusion (37.2% vs. 37.3%, p = 0.99). Overall, the most common adverse effects were agitation (7.3%) and nausea (7.0%).

CONCLUSION: The analgesic efficacy and safety of high-dose sub-dissociative ketamine (≥0.3 mg/kg) was not superior to low-dose (< 0.3 mg/kg) for the management of acute pain in the ED. Low-dose ketamine <0.3 mg/kg is an effective and safe pain management strategy in this population.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Beaudrie-Nunn AN, Wieruszewski ED, Woods EJ, et al. Efficacy of analgesic and sub-dissociative dose ketamine for acute pain in the emergency department. Am J Emerg Med. 2023. PMID: 37290249. doi:10.1016/j.ajem.2023.05.026

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。